Így kezeljük az autológ ossejt-Transzplantáció után kiújult Hodgkin-lymphomát

Translated title of the contribution: Treatment of relapsed Hodgkin lymphoma after autologous stem cell Transplantation

A. Illés, Simon Zsófia, M. Udvardy, Magyari Ferenc, Jóna Ádám, Miltényi Zsófia

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Approximately 10-30% of Hodgkin lymphoma patients relapses or experience refractory disease after first line treatment. Nowadays, autologous stem cell transplantation can successfully salvage half of these patients, median overall survival is only 2-2.5 years. Several prognostic factors determine success of autologous stem cell transplantation. Result of transplantation can be improved considering these factors and using consolidation treatment, if necessary. Patients who relapse after autologous transplantation had worse prognosis, treatment of this patient population is unmet clinical need. Several new treatment options became available in the recent years (brentuximab vedotin and immuncheckpoint inhibitors). These new treatment options offer more chance for cure in relapsed/refractory Hodgkin patients. Outcome of allogenic stem cell transplantation can be improved by using haploidentical donors. New therapeutic options will be discussed in this review.

Original languageHungarian
Pages (from-to)1338-1345
Number of pages8
JournalOrvosi Hetilap
Volume158
Issue number34
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Stem Cell Transplantation
Hodgkin Disease
Therapeutics
Recurrence
Autologous Transplantation
Transplantation
Tissue Donors
Survival
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Így kezeljük az autológ ossejt-Transzplantáció után kiújult Hodgkin-lymphomát. / Illés, A.; Zsófia, Simon; Udvardy, M.; Ferenc, Magyari; Ádám, Jóna; Zsófia, Miltényi.

In: Orvosi Hetilap, Vol. 158, No. 34, 01.08.2017, p. 1338-1345.

Research output: Contribution to journalReview article

Illés, A. ; Zsófia, Simon ; Udvardy, M. ; Ferenc, Magyari ; Ádám, Jóna ; Zsófia, Miltényi. / Így kezeljük az autológ ossejt-Transzplantáció után kiújult Hodgkin-lymphomát. In: Orvosi Hetilap. 2017 ; Vol. 158, No. 34. pp. 1338-1345.
@article{b3d97110741546378e37eefa40d059e5,
title = "{\'I}gy kezelj{\"u}k az autol{\'o}g ossejt-Transzplant{\'a}ci{\'o} ut{\'a}n ki{\'u}jult Hodgkin-lymphom{\'a}t",
abstract = "Approximately 10-30{\%} of Hodgkin lymphoma patients relapses or experience refractory disease after first line treatment. Nowadays, autologous stem cell transplantation can successfully salvage half of these patients, median overall survival is only 2-2.5 years. Several prognostic factors determine success of autologous stem cell transplantation. Result of transplantation can be improved considering these factors and using consolidation treatment, if necessary. Patients who relapse after autologous transplantation had worse prognosis, treatment of this patient population is unmet clinical need. Several new treatment options became available in the recent years (brentuximab vedotin and immuncheckpoint inhibitors). These new treatment options offer more chance for cure in relapsed/refractory Hodgkin patients. Outcome of allogenic stem cell transplantation can be improved by using haploidentical donors. New therapeutic options will be discussed in this review.",
keywords = "Brentuximab vedotin, Haploidentical transplantation, Hodgkin lymphoma, PD1 inhibitor, Relapse",
author = "A. Ill{\'e}s and Simon Zs{\'o}fia and M. Udvardy and Magyari Ferenc and J{\'o}na {\'A}d{\'a}m and Milt{\'e}nyi Zs{\'o}fia",
year = "2017",
month = "8",
day = "1",
doi = "10.1556/650.2017.30823",
language = "Hungarian",
volume = "158",
pages = "1338--1345",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "34",

}

TY - JOUR

T1 - Így kezeljük az autológ ossejt-Transzplantáció után kiújult Hodgkin-lymphomát

AU - Illés, A.

AU - Zsófia, Simon

AU - Udvardy, M.

AU - Ferenc, Magyari

AU - Ádám, Jóna

AU - Zsófia, Miltényi

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Approximately 10-30% of Hodgkin lymphoma patients relapses or experience refractory disease after first line treatment. Nowadays, autologous stem cell transplantation can successfully salvage half of these patients, median overall survival is only 2-2.5 years. Several prognostic factors determine success of autologous stem cell transplantation. Result of transplantation can be improved considering these factors and using consolidation treatment, if necessary. Patients who relapse after autologous transplantation had worse prognosis, treatment of this patient population is unmet clinical need. Several new treatment options became available in the recent years (brentuximab vedotin and immuncheckpoint inhibitors). These new treatment options offer more chance for cure in relapsed/refractory Hodgkin patients. Outcome of allogenic stem cell transplantation can be improved by using haploidentical donors. New therapeutic options will be discussed in this review.

AB - Approximately 10-30% of Hodgkin lymphoma patients relapses or experience refractory disease after first line treatment. Nowadays, autologous stem cell transplantation can successfully salvage half of these patients, median overall survival is only 2-2.5 years. Several prognostic factors determine success of autologous stem cell transplantation. Result of transplantation can be improved considering these factors and using consolidation treatment, if necessary. Patients who relapse after autologous transplantation had worse prognosis, treatment of this patient population is unmet clinical need. Several new treatment options became available in the recent years (brentuximab vedotin and immuncheckpoint inhibitors). These new treatment options offer more chance for cure in relapsed/refractory Hodgkin patients. Outcome of allogenic stem cell transplantation can be improved by using haploidentical donors. New therapeutic options will be discussed in this review.

KW - Brentuximab vedotin

KW - Haploidentical transplantation

KW - Hodgkin lymphoma

KW - PD1 inhibitor

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=85028090479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028090479&partnerID=8YFLogxK

U2 - 10.1556/650.2017.30823

DO - 10.1556/650.2017.30823

M3 - Review article

C2 - 28823212

AN - SCOPUS:85028090479

VL - 158

SP - 1338

EP - 1345

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 34

ER -